Form DEFA14A ALBEMARLE CORP
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________________________________________________________
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
| Filed by the Registrant | X | |||||||
| Filed by a Party other than the Registrant | ||||||||
Check the appropriate box:
| Preliminary Proxy Statement | ||||||||
| Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | ||||||||
| Definitive Proxy Statement | ||||||||
| X | Definitive Additional Materials | |||||||
| Soliciting Material Under Rule 14a-12 | ||||||||
| ALBEMARLE CORPORATION | ||||||||||||||
(Name of registrant as specified in its charter) | ||||||||||||||
| N/A | ||||||||||||||
| (Name of person(s) filing proxy statement, if other than the registrant) | ||||||||||||||
Payment of Filing Fee (Check all boxes that apply):
| X | No fee required. | |||||||
| Fee paid with preliminary materials. | ||||||||
| Fee computed on table on exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. | ||||||||


Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Upgrades Albemarle (ALB) to Buy
- Vividion Therapeutics Doses First Patient in Phase Ib Combination Study of WRN Inhibitor VVD-214 in Patients with Advanced Colorectal Cancer
- TotalEnergies SE: Disclosure of Transactions in Own Shares
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share